Logo

Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer

Share this

Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer

Shots:

  • The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or metastatic NSCLC
  • The trial did not meet its 1EPs of OS and PFS and showed improvements in PFS & OS in pre-specified subgroups of patients based on the baseline inflammatory biomarker- hs-CRP along with other biomarker-defined subgroups
  • The results further support the continued study of P-III CANOPY-A for canakinumab in earlier stages of lung cancer as potential adjuvant & P-II CANOPY-N study in the neoadjuvant therapies. Patients in the CANOPY-A study more closely reflect the earlier CANTOS study population compared to the CANOPY-1 trial

 ­ Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions